Charleen Ml Chan Wah Hak

12PUBLICATIONS
87CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 15, 2026
Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

|Oct 12, 2026
Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer.

|Jul 30, 2026
"SMAC"-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

Pageof 2

Frequent Collaborators

10 joint publications

Kevin J Harrington

9 joint publications

Alan Melcher

8 joint publications

Emmanuel Christian Patin

7 joint publications

Antonio Rullan